Cardiac troponin market seen doubling to $9.4 billion by 2033

By AI, Created 5:25 PM UTC, May 18, 2026, /AGP/ – Persistence Market Research says the global cardiac troponin market is on track to nearly double by 2033, driven by rising cardiovascular disease, broader clinical use and adoption of high-sensitivity assays. North America leads now, while Asia Pacific is expected to grow fastest over the forecast period.

Why it matters: - Cardiac troponin is a core biomarker for detecting myocardial injury and helping diagnose heart attacks. - Demand is rising as cardiovascular disease remains the world’s leading cause of death. - The move to high-sensitivity cardiac troponin assays is reshaping emergency cardiology and expanding testing use.

What happened: - Persistence Market Research projects the global cardiac troponin market will reach $4.7 billion in 2026 and $9.4 billion by 2033. - The forecast implies a 10.4% compound annual growth rate from 2026 to 2033. - The report says the market is expanding because of rising cardiovascular disease, advanced diagnostics and broader adoption of high-sensitivity assays. - The report includes a free sample and a customization request, and the complete market report is available online.

The details: - Troponin T and troponin I are the main types used in clinical practice. - Troponin I is projected to hold about 58% of revenue in 2026. - Troponin T is expected to be the fastest-growing troponin type from 2026 to 2033. - Hospitals are expected to account for nearly 65% of revenue in 2026. - Diagnostic laboratories are forecast to be the fastest-growing end-user segment. - North America is projected to hold about 42% of the market in 2026, supported by advanced healthcare infrastructure and high cardiovascular disease prevalence. - Asia Pacific is expected to post the fastest growth during the forecast period, driven by higher disease incidence and greater healthcare investment. - Europe is expected to grow steadily, helped by an aging population, preventive care and digital health adoption. - The market spans laboratory testing and point-of-care testing across North America, Europe, East Asia, South Asia and Oceania, Latin America, and the Middle East and Africa.

Between the lines: - The report points to a shift from conventional troponin testing toward high-sensitivity platforms, which favors larger hospitals and better-funded health systems. - High acquisition, maintenance and reagent costs remain a barrier for smaller providers, especially in developing markets. - Regulatory differences under U.S. FDA, European IVDR and Asia Pacific frameworks add complexity and can slow broad assay standardization. - The market is moving beyond acute coronary syndrome into heart failure monitoring, myocarditis, infection-related injury and chemotherapy-induced cardiotoxicity. - AI and digital health integration is emerging as a differentiator, with troponin data increasingly combined with ECGs and patient history for triage support. - Roche Diagnostics, Abbott Laboratories, Siemens Healthineers and Beckman Coulter lead a moderately consolidated market that the report says captures 55% to 60% of share. - Recent development activity includes saliva-based troponin sensors from BITS Pilani Hyderabad, Roche’s sixth-generation hs Troponin T assay and low-cost predictive blood tests for early cardiovascular risk detection.

What’s next: - The report expects continued growth in high-sensitivity assays as emergency cardiology workflows shift toward faster and more accurate triage. - Diagnostic laboratories should gain share as testing becomes more scalable and routine. - Broader clinical applications beyond acute myocardial infarction are likely to support longer-term demand. - Ongoing assay harmonization efforts could improve comparability and speed adoption across regions.

The bottom line: - Cardiac troponin testing is becoming a bigger, broader and more digital market, with the strongest growth expected in regions and settings that can afford high-sensitivity diagnostics.